CoChat

Immunology and immunotherapy of cholangiocarcinoma

Open access
Greten, Tim F., Schwabe, Robert, Bardeesy, Nabeel, Ma, Lichun, Goyal, Lipika, Kelley, Robin K., Wang, Xin W. · 2023 · Nature Reviews Gastroenterology & Hepatology
Cited by 193

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have been the only treatment options for decades. Progress in our molecular understanding of the disease and the identification of druggable targets, such as IDH1 mutations and FGFR2 fusions, has provided new treatment options. Immunotherapy has emerged as a potent strategy for many different types of cancer and has shown efficacy in combination with chemotherapy for cholangiocarcinoma. In this Review, we discuss findings related to key immunological aspects of cholangiocarcinoma, including the heterogeneous landscape of immune cells within the tumour microenvironment, the immunomodulatory effect of the microbiota and IDH1 mutations, and the association of immune-related signatures and patient outcomes. We introduce findings from preclinical immunotherapy studies, discuss future immune-mediated treatment options, and provide a summary of results from clinical trials testing immune-based approaches in patients with cholangiocarcinoma. This Review provides a thorough survey of our knowledge on immune signatures and immunotherapy in cholangiocarcinoma. Biliary tumours are surrounded by a desmoplastic tumour microenvironment dominated by cancer-associated fibroblasts and myeloid and macrophage cell populations with immunosuppressive function. Different molecular subtypes based on immune profiles have been described for patients with cholangiocarcinoma and might be usable for patient stratification. The advent of mouse cholangiocarcinoma models in immunocompetent mice allows the development and testing of novel immune-based treatment options for cholangiocarcinoma. Combined chemotherapy with immunotherapy has become the standard-of-care systemic frontline treatment option for patients with cholangiocarcinoma. Various immune-based therapies are currently being tested in patients with cholangiocarcinoma. Cholangiocarcinoma is the second most common primary liver cancer, and its incidence is rising worldwide. This Review discusses the immunology of cholangiocarcinoma and provides a comprehensive overview of the preclinical and clinical immunotherapy studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41575-022-00741-4

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 193

Metadata

Authors
Greten, T. F., Schwabe, R., Bardeesy, N., Ma, L., Goyal, L., Kelley, R. K., & Wang, X. W.
Venue
Nature Reviews Gastroenterology & Hepatology
Published
2023-01-25
Volume
20
Issue
6
Pages
349-365
ISSN
  • 1759-5045 (ISSN-L)
  • 1759-5053
OpenAlex
W4317934751
Cited by
193
References
46
FWCI
16.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunology and immunotherapy of cholangiocarcinoma. https://app.cochat.ai/papers/10.1038/s41575-022-00741-4
The paper
Greten, T. F., Schwabe, R., Bardeesy, N., Ma, L., Goyal, L., Kelley, R. K., & Wang, X. W. (2023). Immunology and immunotherapy of cholangiocarcinoma. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-022-00741-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.